Compare CSTE & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTE | PSTV |
|---|---|---|
| Founded | 1987 | 1996 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7M | 27.9M |
| IPO Year | 2012 | 2016 |
| Metric | CSTE | PSTV |
|---|---|---|
| Price | $1.42 | $3.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $55.00 |
| AVG Volume (30 Days) | 2.8M | ★ 4.4M |
| Earning Date | 05-06-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,213,000.00 |
| Revenue This Year | $3.43 | $21.93 |
| Revenue Next Year | $2.83 | $279.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.56 | $0.13 |
| 52 Week High | $3.26 | $3.84 |
| Indicator | CSTE | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 63.06 | 84.26 |
| Support Level | $1.42 | $0.37 |
| Resistance Level | $1.75 | N/A |
| Average True Range (ATR) | 0.16 | 0.22 |
| MACD | 0.08 | 0.38 |
| Stochastic Oscillator | 96.32 | 92.07 |
Caesarstone Ltd manufactures engineered quartz surfaces. Its products include engineered quartz and porcelain slabs, which are used as kitchen countertops in renovation and remodeling, and residential construction. It also has other applications, including vanity tops, wall panels, backsplashes, floor tiles, stairs, and other interior surfaces that are used in various residential and non-residential applications. The company sells its products under the Caesarstone brand. Caesarstone's geographical segments are the United States, Canada, Latin America, Australia, Asia, Israel, and EMEA(Europe, Middle East, Africa).
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).